Role of Nrf2 in cancer photodynamic therapy: Regulation of human ABC transporter ABCG2

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3058-3069

  Ishikawa, Toshihisa ^a   Kajimoto, Yoshinaga ^b   Sun, Wei ^b,c   Nakagawa, Hiroshi ^d   Inoue, Yutaka ^e   Ikegami, Yoji ^e   Miyatake, Shin Ichi ^b   Kuroiwa, Toshihiko ^b  

^a RIKEN   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c SHANGHAI PUNAN HOSPITAL   (China)

^d CHUBU UNIVERSITY   (Japan)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ABC transporters; Aminolevulinic acid (ALA); Cancer; Gefitinib; Metabolism; MRNA; Nrf2; Oxidative stress; Porphyrin; Single nucleotide polymorphism (SNP)

Indexed keywords

AMINOLEVULINIC ACID; BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; IMATINIB; PORPHYRIN; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER THERAPY; GLIOBLASTOMA; HUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ABC TRANSPORTERS; AMINOLEVULINIC ACID (ALA); CANCER; GEFITINIB; METABOLISM; MRNA; NRF2; OXIDATIVE STRESS; PORPHYRIN; SINGLE NUCLEOTIDE POLYMORPHISM (SNP);

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NF-E2-RELATED FACTOR 2; PHOTOCHEMOTHERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; PORPHYRINS; REACTIVE OXYGEN SPECIES; TRANSCRIPTIONAL ACTIVATION;

EID: 84881609328     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23563     Document Type: Review

References (97)

1. Latunde-Dada GO, Simpson RJ, McKie AT. 2006. Recent advances in mammalian haem transport. Trends Biochem Sci 31:182-188.
2. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. 2006. Heme as key regulator of major mammalian cellular functions: Molecular, cellular, and pharmacological aspects. Pharmacol Ther 111:327-345.
3. Dubakiene R, Kupriene M. 2006. Scientific problems of photosensitivity. Medicina (Kaunas) 42:619-624.
4. Hindmarsh JT. 2003. The porphyrias, appropriate test selection. Clin Chim Acta 333:203-207.
5. Norman RA. 2005. Past and future: Porphyria and porphyrins. Skinmed 4:287-292.
6. Dolmans DE, Fukumura D, Jain RK. 2003. Photodynamic therapy for cancer. Nat Rev Cancer 3:380-387.
7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. 1998. Photodynamic therapy. J Natl Cancer Inst 90:889-905.
8. Buytaert E, Dewaele M, Agostinis P. 2007. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776:86-107.
9. Itoh K, Igarashi K, Hayashi N, Nishizawa M, Yamamoto M. 1995. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol 15:4184-4193.
10. Moi P, Chan K, Asunis I, Cao A, Kan YW. 1994. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91:9926-9930.
11. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, Yamamoto M. 2006. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26:221-229.
12. Kobayashi M, Yamamoto M. 2006. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46:113-140.
13. Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT, Ishikawa T. 2007. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol 6:335-348.
14. Krishnamurthy P, Xie T, Schuetz JD. 2007. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 114:345-358.
15. Wakabayashi K, Tamura A, Saito H, Onishi Y, Ishikawa T. 2006. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev 38:371-391.
16. Ishikawa T, Nakagawa H, Hagiya Y, Nonoguchi N, Miyatake S, Kuroiwa T. 2010. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Adv Pharm Sci 2010:587306.
17. Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, Ishikawa T. 2006. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70:287-296.
18. Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, Hoshijima K, Priebe W, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. 2007. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet 22:428-440.
19. Tamura A, An R, Hagiya Y, Hoshijima K, Yoshida T, Mikuriya K, Ishikawa T. 2008. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: Development of in vitro high-speed screening systems. Expert Opin Drug Metab Toxicol 4:255-272.
20. Robey RW, Steadman K, Polgar O, Bates SE. 2005. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biol Ther 4:187-194.
21. Hagiya Y, Adachi T, Ogura S, An R, Tamura A, Nakagawa H, Okura I, Mochizuki T, Ishikawa T. 2008. Nrf2-dependent induction of human ABC transporter ABCG2 and hemeoxygenase-1 in HepG2 cells by photoactivation of porphyrins: Biochemical implications for cancer cell response to photodynamic therapy. J Exp Ther Oncol 7:153-167.
22. Motohashi H, Yamamoto M. 2004. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10:549-557.
23. Toyoda Y, Hagiya Y, Asdachi T, Hoshijima K, Kuo MT, Ishikawa T. 2008. MRP class of human ABC transporters: Historiacal background and new research directions. Xenobiotica 38:833-862, 2008.
24. Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB. 2005. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280:32485-32492.
25. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, Yamamoto M. 2008. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28:2758-2770.
26. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A. 2004. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279:8919-8929.
27. Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, de Witte P, Agostinis P. 2007. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 12:731-741.
28. Andreadi CK, Howells LM, Atherfold PA, Manson MM. 2006. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol 69:1033-1040.
29. Bloom DA, Jaiswal AK. 2003. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 278:44675-44682.
30. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. 2003. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23:7198-7209.
31. Cullinan SB, Diehl JA. 2004. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 279:20108-20117.
32. Kang KA, Lee KH, Park JW, Lee NH, Na HK, Surh YJ, You HJ, Chung MH, Hyun JW. 2007. Triphlorethol-A induces heme oxygenase-1 via activation of ERK and NF-E2 related factor 2 transcription factor. FEBS Lett 581:2000-2008.
33. Kang KW, Lee SJ, Park JW, Kim SG. 2002. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 62:1001-1010.
34. Igarashi K, Sun J. 2006. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal 8:107-118.
35. Oyake T, Itoh K, Motohashi H, Hayashi N, Hoshino H, Nishizawa M, Yamamoto M, Igarashi K. 1996. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16:6083-6095.
36. Sun J, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, Tashiro S, Takahashi S, Shibahara S, Alam J, Taketo MM, Yamamoto M, Igarashi K. 2002. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 21:5216-5224.
37. Sun J, Brand M, Zenke Y, Tashiro S, Groudine M, Igarashi K. 2004. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci USA 101:1461-1466.
38. Hintze KJ, Katoh Y, Igarashi K, Theil EC. 2007. Bach1 repression of ferritin and thioredoxin reductase1 is heme-sensitive in cells and in vitro and coordinates expression with heme oxygenase1, beta-globin, and NADP(H) quinone (oxido) reductase1. J Biol Chem 282:34365-34371.
39. Kitamuro T, Takahashi K, Ogawa K, Udono-Fujimori R, Takeda K, Furuyama K, Nakayama M, Sun J, Fujita H, Hida W, Hattori T, Shirato K, Igarashi K, Shibahara S. 2003. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem 278:9125-9133.
40. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. 2006. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J 20:2651-2653.
41. Ogawa K, Sun J, Taketani S, Nakajima O, Nishitani C, Sassa S, Hayashi N, Yamamoto M, Shibahara S, Fujita H, Igarashi K. 2001. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J 20:2835-2843.
42. Suzuki H, Tashiro S, Hira S, Sun J, Yamazaki C, Zenke Y, Ikeda-Saito M, Yoshida M, Igarashi K. 2004. Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. EMBO J 23:2544-2553.
43. Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, Tokunaga F, Iwai K, Igarashi K. 2007. Heme induces ubiquitination and degradation of the transcription factor Bach1. Mol Cell Biol 27:6962-6971.
44. Reichard JF, Motz GT, Puga A. 2007. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res 35:7074-7086.
45. +-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther 32:220-228.
46. Babilas P, Landthaler M, Szeimies RM. 2006. Photodynamic therapy in dermatology. Eur J Dermatol 16:340-348.
47. Huber RM, Gamarra F, Hautmann H, Häußinger K, Wagner S, Castro M, Baumgartner R. 1999. 5-Aminolaevulinic Acid (ALA) for the fluorescence detection of bronchial tumors. Diagn Ther Endosc 5:113-118.
48. Inoue K, Fukuhara H, Shimamoto T, Kamada M, Iiyama T, Miyamura M, Kurabayashi A, Furihata M, Tanimura M, Watanabe H, Shuin T. 2012. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 118:1062-1074.
49. Hillemanns P, Weingandt H, Baumgartner R, Diebold J, Xiang W, Stepp H. 2000. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. Cancer 88:2275-2282.
50. Löning M, Diddens H, Küpker W, Diedrich K, Hüttmann G. 2004. Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 100:1650-1656.
51. Zaak D, Sroka R, Khoder W, Adam C, Tritschler S, Karl A, Reich O, Knuechel R, Baumgartner R, Tilki D, Popken G, Hofstetter A, Stief CG. 2008. Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid-First clinical experiences. Urology 72:345-348.
52. Kajimoto Y, Kuroiwa T, Miyatake SI, Ichioka T, Miyashita M, Tanaka H, Tsuji M. 2007. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg 106:1070-1074.
53. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. 2000. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93:1003-1013.
54. Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H. 2006. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401.
55. Miyatake SI, Kuroiwa T, Kajimoto Y, Miyashita M, Tanaka H, Tsuji M. 2007. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: Case report. Neurosurgery 61:E1101-E1104.
56. Tamura Y, Kuroiwa T, Kajimoto Y, Miki Y, Miyatake SI, Tsuji M. 2007. Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note. J Neurosurg 106:507-510.
57. Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H, Stummer W, Baumgartner R. 2007. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39:386-393.
58. Stummer W, Beck T, Beyer W, Mehrkens JH, Obermeier A, Etminan N, Stepp H, Tonn J-C, Baumgartner R, Herms J, Kreth FW. 2008. Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: Case report. J Neurooncol 87:103-109.
59. Barnett A, Haller JC, Cairnduff F, Lane G, Brown SB, Roberts DJH. 2003. A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer 103:829-832.
60. Cairnduff F, Stringer M, Hudson E, Ash D, Brown S. 1994. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 69:605-608.
61. Olzowy B, Hundt CS, Stocker S, Bise K, Reulen HJ, Stummer W. 2002 Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J Neurosurg 97:970-976.
62. Angell-Petersen E, Spetalen S, Madsen SJ, Sun CH, Peng Q, Carper SW, Sioud M, Hirschberg H. 2006. Influence of light fluorescence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg 104:109-117.
63. Mathews MS, Angell-Petersen E, Sanchez R, Sun CH, Vo V, Hirschberg H, Madsen SJ. 2009. The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers Surg Med 41:578-584.
64. Anand S, Honari G, Hasan T, Elson P, Maytin EV. 2009. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 15:3333-3343.
65. Robey RW, Polgar O, Deeken J, To KW, Bates SE. 2007. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39-57.
66. Basseville A, Susan E, Bates SE, Figg WD, Sparreboom A. 2013. BCRP (ABCG2). In Pharmacogenomics of human drug transporters: Clinical impacts; Ishikawa T, Kim RB, Konig J, Eds. Wiley, Hoboken NJ pp 311-349.
67. Busch TM, Hahn SM. 2005. Multidrug resistance in photodynamic therapy. Cancer Biol Ther 4:195-196.
68. Krishnamurthy P, Schuetz JD. 2011. The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. Curr Pharm Biotechnol 12:647-655.
69. Ishikawa T, Takahashi K, Ikeda N, Kajimoto Y, Hagiya Y, Ogura S, Miyatake S, Kuroiwa T. 2011. Transporter-mediated drug interaction strategy for ALA-based photodynamic diagnosis of malignant brain tumor: Molecular design of ABCG2 inhibitors. Pharmaceutics 3:615-635.
70. Hagiya H, Endo Y, Yonemura Y, Takahashi K, Ishizuka M, Abe F, Tanaka T, Okura I, Nakajima M, Ishikawa T, Ogura S. 2012. Pivotal role of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based phototoxicity of gastric cancer cells in vitro. Photodiagn Photodyn Ther 9:204-214.
71. Ishikawa T, Tamura A, Saito H, Wakabayashi K, Nakagawa H. 2005. Pharmacogenomics of the human ABC transporter ABCG2: From functional evaluation to drug molecular design. Naturwissenschaften 92:451-463.
72. Liu W, Baer, MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR. 2007. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 13:2463-2470.
73. An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, Ishikawa T. 2009. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res 26:449-458.
74. Sun W, Kajimoto Y, Miyatake S, Ishikawa T, Kuroiwa T. 2013. Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells. Photodiagnosis and Photodynamic Therapy 10:42-50.
75. Jozkowicz A, Was H, Dulak J. 2007. Heme oxygenase-1 in tumors: Is it a false friend? Antioxid Redox Signal 9:2099-2117.
76. Gomer CJ, Luna M, Ferrario A, Rucker N. 1991. Increased transcription and translation of heme oxygenase in Chinese hamster fibroblasts following photodynamic stress or Photofrin II incubation. Photochem Photobiol 53:275-279.
77. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Was H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M, Golab J. 2006. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25:3365-3374.
78. Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. 2010. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 9:2365-2376.
79. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Völker U, Kroemer HK. 2006. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34:524-533.
80. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC. 2011. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 286:20558-20568.
81. Nakanishi T, Bailey-Dell KJ, Hassel BA, Shinozawa K, Sullivan DM, Turner J, Ross DD. 2006. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: Implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res 66:5007-5011.
82. Nakanishi T, Ross DD. 2012. Breast cancer resistance protein (BCRP/ABCG2): Its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 31:73-99.
83. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. 2004. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64:1247-1251.
84. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. 2004. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218-24225.
85. Tompkins LM, Li H, Li L, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang H. 2010. A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol 80:1754-1761.
86. To KK, Yu L, Liu S, Fu J, Cho CH. 2011. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog 51:449-464.
87. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, Kwak MK. 2011. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res 7:2260-2275.
88. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K, Yamamoto M. 2009. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15:3423-3432.
89. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. 2012. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:66-79.
90. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, Ishikawa T. 2006. Nuclear receptor-mediated transcription regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 21:437-457
91. Shen G, Kong AN. 2009. Nrf2 plays an important role in coordinated regulation of phase II drug metabolism enzymes and phase III drug transporters. Biopharm Drug Dispos 30:345-55
92. Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT, Ishikawa T. 2007. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol 6:335-348.
93. Yamamoto T, Yoh K, Kobayashi A, Ishii Y, Kure S, Koyama A, Sakamoto T, Sekizawa K, Motohashi H, Yamamoto M. 2004. Identification of polymophisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun 321:72-79.
94. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR. 2007. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 21:2237-2246.
95. Okano Y, Nezu U, Kinoshita H, Miyagi Y, Nakayama H, Yokose T, Morita S, Taguri M, Lezhava A, Ichikawa Y, Kaneko T, Natsumeda Y, Hayashizaki Y, Ishikawa T. in press. SNP (-617C>A) in ARE-like loci of the NRF2 gene: A new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women. PLoS ONE (in press).
96. Hayes JD, McMahon M. 2009. NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 34:176-188.
97. Sporn MB, Liby KT. 2012. NRF2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer 12:564-571.